The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOCs). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We asses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Parmar, Kalindi, Kochupurakkal, Bose S., Lazaro, Jean-Bernard, Wang, Zhigang C., Palakurthi, Sangeetha, Kirschmeier, Paul T., Yang, Chunyu, Sambel, Larissa A., Farkkila, Anniina, Reznichenko, Elizaveta, Reavis, Hunter D, Dunn, Connor E., Zou, Lee, Do, Khanh T., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Liu, Joyce F., D’Andrea, Alan D., Shapiro, Geoffrey I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801076/
https://ncbi.nlm.nih.gov/pubmed/31409614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0448
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados